ALLEN, Texas, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced its results for the fourth quarter ended December 31, 2022 and the full year 2022.
Revenues for the fourth quarter of 2022 totaled $42.9 million compared to $40.3 million for the same period in 2021. For the quarter ended December 31, 2022, operating income was $8.8 million, up $967 thousand over the comparable 2021 period, and net income was $8.3 million, up $195 thousand over the same period in 2021. Fourth quarter 2022 diluted earnings per share were $4.70 compared to $4.50 for the fourth quarter of 2021. For the full year 2022 compared to the full year 2021, revenues increased to $183.5 million from $165.0 million, net income was $35.0 million versus $33.1 million, and diluted earnings per share were $19.56 compared to $18.18.
Commenting on the results of the quarter and the full year compared to prior year periods, David Battat, President and CEO, stated, “We are very pleased with the results of the quarter when, despite supply disruptions, revenues were up 6% to an all-time record amount for a fourth quarter. For the full year 2022, revenues increased 11%, also to a new record level for the Company.” Mr. Battat continued, “Progressively higher costs for labor and raw materials resulted in a 1% drop in gross profit margin, with 2022 concluding at 41% compared to 42% in 2021. Nevertheless, operating income was up 12% for the just-ended quarter and 10% for the year. Net income was up by 2% in the fourth quarter and 6% for the year, adversely impacted by weaker performance in our investment portfolio. Earnings per share were up 8% for the full year, with fewer outstanding shares following the repurchase of 18,828 shares in the fourth quarter at an average cost per share of $603.19 and total repurchases during the full year of 42,568 shares at an average cost per share of $605.78. We remain debt free, despite investing heavily in our future growth. In addition to our ongoing program of aggressive investment in new products and automation, over the last few years we committed $41 million for a new company-wide ERP system and a significant expansion of our Florida facility to meet anticipated future demand.”
Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.
Contact:
Jeffery Strickland
Vice President and Chief Financial Officer
(972) 390-9800
ATRION CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Revenues | $ | 42,855 | $ | 40,293 | $ | 183,506 | $ | 165,009 | |||||||
| Cost of goods sold | 24,681 | 22,917 | 107,602 | 95,637 | |||||||||||
| Gross profit | 18,174 | 17,376 | 75,904 | 69,372 | |||||||||||
| Operating expenses | 9,369 | 9,538 | 36,217 | 33,330 | |||||||||||
| Operating income | 8,805 | 7,838 | 39,687 | 36,042 | |||||||||||
| Interest and dividend income | 349 | 163 | 988 | 843 | |||||||||||
| Other investment income (loss) | (366 | ) | 625 | (150 | ) | 1,477 | |||||||||
| Other income | -- | -- | 92 | 67 | |||||||||||
| Income before income taxes | 8,788 | 8,626 | 40,617 | 38,429 | |||||||||||
| Income tax provision | (466 | ) | (499 | ) | (5,609 | ) | (5,374 | ) | |||||||
| Net income | $ | 8,322 | $ | 8,127 | $ | 35,008 | $ | 33,055 | |||||||
| Income per basic share | $ | 4.70 | $ | 4.51 | $ | 19.59 | $ | 18.22 | |||||||
| Weighted average basic shares outstanding | 1,770 | 1,801 | 1,787 | 1,814 | |||||||||||
| Income per diluted share | $ | 4.70 | $ | 4.50 | $ | 19.56 | $ | 18.18 | |||||||
| Weighted average diluted shares outstanding | 1,771 | 1,806 | 1,790 | 1,818 | |||||||||||
ATRION CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)
| Dec. 31, | Dec. 31, | ||||||
| ASSETS | 2022 | 2021 | |||||
| (Unaudited) | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 4,731 | $ | 32,264 | |||
| Short-term investments | 21,152 | 29,059 | |||||
| Total cash and short-term investments | 25,883 | 61,323 | |||||
| Accounts receivable | 23,951 | 21,023 | |||||
| Inventories | 65,793 | 50,778 | |||||
| Prepaid expenses and other | 3,770 | 3,447 | |||||
| Total current assets | 119,397 | 136,571 | |||||
Long-term investments | 8,669 | 19,423 | |||||
Property, plant and equipment, net | 123,754 | 97,972 | |||||
| Other assets | 12,892 | 13,298 | |||||
| $ | 264,712 | $ | 267,264 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities | 18,098 | 13,346 | |||||
| Line of credit | -- | -- | |||||
| Other non-current liabilities | 7,073 | 9,622 | |||||
| Stockholders’ equity | 239,541 | 244,296 | |||||
| $ | 264,712 | $ | 267,264 | ||||
| Last Trade: | US$402.35 |
| Daily Change: | 16.65 4.32 |
| Daily Volume: | 38,508 |
| Market Cap: | US$708.140M |
February 29, 2024 November 07, 2023 September 20, 2023 August 08, 2023 May 23, 2023 | |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
